Dr. Stella Kang weighs in on prostate MRIs
“It is always important to think about how the imaging and the way we read the imaging can improve, right and be used in a way that makes the most sense for the decision at hand,” says Stella K. Kang, MD, in this podcast.
In this episode, Urology Times® Managing Editor Ben Saylor spoke with Dr. Stella K. Kang. She discusses the recent Radiology study titled, "Active Surveillance Strategies for Low-Grade Prostate Cancer: Comparative Benefits and Cost-effectiveness,” for which she served as a study author. Kang is an associate professor of radiology and population health and director of Comparative Effectiveness and Outcomes Research in the department of radiology at NYU Grossman School of Medicine, New York.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.
